Cargando…

The effect of adjuvant cyclophosphamide or tamoxifen on the numbers of lymphocytes bearing T cell or NK cell markers.

Detalles Bibliográficos
Autores principales:	Sheard, C. R., Reilly, F., Tee, D. E., Vergani, D., Lowe, D., Baum, M., Cameron, A. E.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1986
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001508/ https://www.ncbi.nlm.nih.gov/pubmed/3490874

Ejemplares similares

Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party.
Publicado: (1988)

Uracil-tegafur and tamoxifen versus cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
por: Park, Y, et al.
Publicado: (2009)

Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
por: Pinzón-García, Ana D., et al.
Publicado: (2021)

Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study
por: Park, Y, et al.
Publicado: (2009)

Adjuvant tamoxifen for early breast cancer.
por: Smith, I.
Publicado: (1988)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial.
por: Blomqvist, C., et al.
Publicado: (1992)

Adjuvant tamoxifen for male breast cancer (MBC).
por: Ribeiro, G., et al.
Publicado: (1992)

Granulosa cell tumor of the ovary and antecedent of adjuvant tamoxifen use for breast cancer
por: Abahssain, Halima, et al.
Publicado: (2010)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases
por: Quintieri, L, et al.
Publicado: (1999)

Has tamoxifen had its day?
por: Baum, Michael
Publicado: (2002)

Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404
por: Shien, Tadahiko, et al.
Publicado: (2014)

Proceedings: Hormones in breast cancer patients on tamoxifen.
por: Golder, M. P., et al.
Publicado: (1975)

Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen
por: Coradini, D, et al.
Publicado: (2003)

Tamoxifen--the treatment of choice. Why look for alternatives?
por: Baum, M.
Publicado: (1998)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

The Christie hospital adjuvant tamoxifen trial--status at 10 years.
por: Ribeiro, G., et al.
Publicado: (1988)

Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer
por: Martinez-Cannon, Bertha Alejandra, et al.
Publicado: (2021)

Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors
por: Uslu, Yasemin, et al.
Publicado: (2023)

NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy
por: Mozaffari, F, et al.
Publicado: (2007)

Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer
por: Adeel, Muhammad, et al.
Publicado: (2019)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment
por: Beelen, Karin, et al.
Publicado: (2014)

Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis
por: Al-Mubarak, Mustafa, et al.
Publicado: (2014)

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk
por: Pistilli, Barbara, et al.
Publicado: (2020)

Polytherapeutic strategies with oncolytic virus–bortezomib and adjuvant NK cells in cancer treatment
por: Aspirin, Angelica P., et al.
Publicado: (2021)

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
por: Province, M A, et al.
Publicado: (2014)

Urinary bladder hemangiosarcoma in a cat treated with partial cystectomy and adjuvant metronomic cyclophosphamide and thalidomide
por: McNally, Abigail, et al.
Publicado: (2023)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

NK Cell Isolation from Liver Biopsies: Phenotypic and Functional Analysis of Low Cell Numbers by Flow Cytometry
por: Li, Ning, et al.
Publicado: (2013)

Increased Numbers of NK Cells, NKT-Like Cells, and NK Inhibitory Receptors in Peripheral Blood of Patients with Chronic Obstructive Pulmonary Disease
por: Tang, Ying, et al.
Publicado: (2013)

Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer
por: Gwak, Geumhee, et al.
Publicado: (2011)

After cyclophosphamide exposure, granulosa cells recover their anti‐müllerian hormone‐producing ability but not their numbers
por: Kim, Jihyun, et al.
Publicado: (2020)

Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides
por: Venhoff, Nils, et al.
Publicado: (2012)

Diuretic response to cyclophosphamide in rats bearing a matrix metalloproteinase-9-producing tumour.
por: Mizushima, Y., et al.
Publicado: (1998)

Beneficial effects of 20(S)-protopanaxadiol on antitumor activity and toxicity of cyclophosphamide in tumor-bearing mice
por: LIN, GUANGZHU, et al.
Publicado: (2013)

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
por: Cuzick, J, et al.
Publicado: (2006)

Radiation recall dermatitis induced by tamoxifen during adjuvant breast cancer treatment
por: Rhee, Jiyoung, et al.
Publicado: (2014)

Identification of Human NK17/NK1 Cells
por: Pandya, Abhilash D., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_sadqe8eqh506jhl0l5os8omb2j